The pharmacokinetics and extra-hepatic clearance of remifentanil, a short acting opioid agonist, in male beagle dogs during constant rate infusions

Drug Metabolism and Disposition

Volumn 24, Issue 1, 1996, Pages 34-40

  Chism, J P ^a   Rickert, D E ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 METHOXYCARBONYL 4 (N PHENYLPROPIONAMIDO)PIPERIDINO]PROPIONIC ACID ETHYL ESTER; BARBITAL; GI 95779; MU OPIATE RECEPTOR; OPIATE AGONIST; PENTOBARBITAL; REMIFENTANIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INFUSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN RESIDENCE TIME; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANALGESICS, OPIOID; ANIMALS; DOGS; HALF-LIFE; INJECTIONS, INTRAVENOUS; LIVER; MALE; PIPERIDINES;

ANIMALIA; CANIS FAMILIARIS;

EID: 0030067891     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. P. L. Feldman, M. K. James, M. F. Breckeen, J. M. Bilotta, S. V. Schuster, A. P. Lahey, M. W. Lutz, M. R. Johnson, and H. J. Leighton: Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgetics. J. Med. Chem. 34, 2201-2208 (1991).
2. M. K. James: Remifentanil and anesthesia for the future. Expert Opinion on Investigational Drugs 3, 331-340 (1994).
3. M. Chauvin, F. Bonnet, C. Momembault, J. Levron, and P. Viars: The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans. Measurement of alfentanil hepatic extraction coefficient. Anesth. Analg. 65, 999-1003 (1986).
4. C. Ferrier, J. Marry, Y. Bouffard, J. P. Haberer, J. C. Levron, and P. Duvaldestin: Alfentanil pharmacokinetics in patients with cirrhosis. Anesthesiology, 62, 480-484 (1985).
5. V. Fiserova-Bergerova and H. Hughes: Species differences on bioavailability of inhaled vapors and gases. In: "Modeling of Inhalation Exposure to Vapors: Uptake, Distribution, and Elimination" (V. Fiserova-Bergerova, ed.), vol. 2. pp. 97-106. CRC Press, Boca Raton, FL, 1983.
6. B. Davies and T. Morris: Physiological parameters in laboratory animals and humans. Pharm Res 10, 1093-1095 (1993).
7. J. E. Ilkiw, J. A. Benthusysen, and D. McNeal: Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. Am. J. Vet. Res. 52, 581-584 (1991).
8. T. Egan, H. Lemmens, P. Fiset, D. Hermann, K. Muir, D. Stanski, and S Shafer: The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology 79, 881-892 C1993).
9. C. Westmorland, J. Hoke, P. Sebel, C. Hug, and K. Muir: Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology 79, 893-903 (1993).
10. S. Gelman. Disturbances in hepatic blood flow during anesthesia and surgery. Arch. Surg. 111, 881-883 (1976).
11. S. Bower and C. Hull: Comparative pharmacokinetics of fentanyl and alfentanil. Br. J. Anaesth. 54, 871-877 (1982).